Proteomic risk markers for coronary heart disease and stroke: validation and mediation of randomized trial hormone therapy effects on these diseases.
Seattle, United States. In Genome Med, 27 Jan 2014
METHODS: Five proteins potentially associated with CHD (beta-2 microglobulin (B2M), alpha-1-acid glycoprotein 1 (ORM1), thrombospondin-1(THBS1), complement factor D pre-protein (CFD), and insulin-like growth factor binding protein 1 (IGFBP1)) and five potentially associated with stroke (B2M, IGFBP2, IGFBP4, IGFBP6, and hemopexin (HPX)) had high discovery phase significance level ranking and an available ELISA assay, and were included in case-control validation studies within the Women's Health Initiative (WHI) hormone therapy trials.
Use of biomarkers in the management of children with lupus.
Innsbruck, Austria. In Curr Rheumatol Rep, Mar 2013
The most promising biomarkers in juvenile-onset SLE include cell-bound complement activation products, some genomic profiles, and urinary proteins such as neutrophil gelatinase-associated lipocalin, monocyte chemoattractant protein-1, and alpha-1-acid glycoprotein.
The urine proteome as a radiation biodosimeter.
Kansas City, United States. In Adv Exp Med Biol, 2012
Analysis of acute-phase response proteins and markers of acute kidney injury showed increased urinary levels of cystatin superfamily proteins and alpha-1-acid glycoprotein.
[Psychotropic medication of elderly patients].
Tokyo, Japan. In Nihon Rinsho, 2012
Drugs medicated for elderly patients show different pharmacokinetics from young patients, because of change in the makeup of bodies, decrease of albumin, increase of alpha-1-acid glycoprotein, hypofunction of metabolism, and excretion by aging.